Rhenman & Partners Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-302,157
| Closed | -$1.24M | – | 96 |
|
|
2018
Q1 | $1.24M | Hold |
302,157
| – | – | 0.15% | 72 |
|
|
2017
Q4 | $1.41M | Sell |
302,157
-97,843
| -24% | -$455K | 0.19% | 77 |
|
|
2017
Q3 | $2.84M | Sell |
400,000
-25,111
| -6% | -$178K | 0.36% | 71 |
|
|
2017
Q2 | $3.07M | Hold |
425,111
| – | – | 0.44% | 73 |
|
|
2017
Q1 | $2.62M | Hold |
425,111
| – | – | 0.41% | 75 |
|
|
2016
Q4 | $2.49M | Sell |
425,111
-75,000
| -15% | -$439K | 0.48% | 67 |
|
|
2016
Q3 | $2.66M | Buy |
500,111
+50,000
| +11% | +$266K | 0.42% | 72 |
|
|
2016
Q2 | $2.98M | Sell |
450,111
-499,889
| -53% | -$3.31M | 0.53% | 64 |
|
|
2016
Q1 | $4.44M | Sell |
950,000
-283,000
| -23% | -$1.32M | 0.88% | 43 |
|
|
2015
Q4 | $6.23M | Sell |
1,233,000
-330,000
| -21% | -$1.67M | 0.94% | 43 |
|
|
2015
Q3 | $5.5M | Buy |
1,563,000
+1,029,000
| +193% | +$3.62M | 0.88% | 46 |
|
|
2015
Q2 | $5.33M | Buy |
534,000
+237,000
| +80% | +$2.37M | 0.64% | 54 |
|
|
2015
Q1 | $3.78M | Buy |
297,000
+206,576
| +228% | +$2.63M | 0.64% | 53 |
|
|
2014
Q4 | $1.28M | Sell |
90,424
-45,576
| -34% | -$645K | 0.37% | 79 |
|
|
2014
Q3 | $1.87M | Sell |
136,000
-104,000
| -43% | -$1.43M | 0.55% | 76 |
|
|
2014
Q2 | $3.69M | Sell |
240,000
-25,325
| -10% | -$389K | 1.1% | 30 |
|
|
2014
Q1 | $4.52M | Sell |
265,325
-134,675
| -34% | -$2.29M | 1.36% | 18 |
|
|
2013
Q4 | $5.18M | Buy |
+400,000
| New | +$5.18M | 2.03% | 12 |
|